The study to find out effects of mixing up Covaxin and Covishiled, the tak vaccines used in India’s Covid-19 vaccination has been approved by the Drugs Controlled General of India (DCGI).
The mixing of vaccines doses,” said Dr VK Paul, member of NITI Aayog(Health), during a press briefing on Tuesday.
The Subject Expert Committee of the Central Drugs Standard Control Organisation (CDSCO) has suggested this study on July 29.
However, this study will be different from the one conducted by Indian Council of Medical Research (ICMR), which said mixing the two Covid vaccines elicited better safety and immunogenicity results.
The mixing up the doses had raised a lot of anxiety.
The study directed on people in Uttar Pradesh got Covishield as the first dose followed by coincidental administration of Covaxin as the second second at a timespan of six weeks.
A sum of 18 members were in the heterologous gathering. Although, two members were reluctant and were excluded. Among them, 11 were male, and seven were female with a middle age of 62 years.
The ICMR said the study proposed inoculation with a blend of an adenovirus vector stage based vaccine followed by an inactivated whole infection vaccine was protected as well as elicited better immunogenicity.
“We did a comparison with heterogeneous group and homologous group, we found better immune response, if somebody gets Covishield first and Covaxin second that it gives better immunity. This is the first study on a combination of Adenovector and whole variant vaccines,” said Dr Samiran Panda, Head of Epidemiology and Communicable Diseases, ICMR.
Meanwhile, the top medical body added that more definite and top to bottom examination should be done on the impediments, as the study is done just on 18 members.